Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.37 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5240232 | 0.91 | CYP24A1 (0.44) | CYP19A1NPC1RAB9AMETAP1SRD5A1 | |
| SCHEMBL5242273 | 0.84 | EGFR (0.41) | CYP19A1NPC1RAB9AMETAP1 | |
| SCHEMBL5238881 | 0.78 | ALK (0.38) | CYP19A1ACHENPC1RAB9AMETAP1 | |
| SCHEMBL5239102 | 0.71 | EGFR (0.45) | CYP19A1 | |
| SCHEMBL11237837 | 0.71 | CYP19A1 (0.61) | CYP19A1ACHEMETAP1MTNR1AMTNR1B | |
| SCHEMBL7513546 | 0.71 | ACHE (0.55) | CYP19A1ACHENPC1RAB9AMETAP1 | |
| SCHEMBL5237018 | 0.70 | ACHE (0.71) | CYP19A1ACHEMETAP1 | |
| SCHEMBL5237022 | 0.70 | ACHE (0.71) | CYP19A1ACHEMETAP1 | |
| SCHEMBL5237012 | 0.70 | ACHE (0.71) | CYP19A1ACHEMETAP1 | |
| SCHEMBL903653 | 0.69 | CYP24A1 (0.50) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1761513-A1 | TETRACYCLIC COMPOUNDS AS ESTROGEN LIGANDS | Wyeth (US) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006007503-A1 | TETRACYCLIC COMPOUNDS AS ESTROGEN LIGANDS | WYETH (US) | 2006-01-19 | — | — | WO | disclosed |
| US-20060004087-A1 | Tetracyclic compounds as estrogen ligands | WYETH (US) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004087-A1 | Tetracyclic compounds as estrogen ligands | ESR1, ESRRA, ESR2 | CYP19A1 18/4885ACHE 2610/4885NPC1 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.